Retatrutide: Phase 2 and Phase 3 Trial Data on the Triple-Agonist GLP-1 Drug

Retatrutide activates three metabolic receptors — GLP-1, GIP, and glucagon — and has produced the largest average weight loss reported in a GLP-1-class trial to date, though its regulatory approval remains pending Phase 3 completion.

How the Triple-Agonist Mechanism Works

Semaglutide is a GLP-1-only agonist. Tirzepatide adds GIP agonism to that base. Retatrutide goes a step further by also activating the glucagon receptor — which is where its mechanism diverges most meaningfully from its predecessors.

Glucagon is typically understood as insulin's counter-hormone, raising blood glucose in the fasting state. However, glucagon receptor activation also increases energy expenditure and promotes fat oxidation in the liver — a mechanistically distinct pathway from the appetite suppression that GLP-1 and GIP primarily drive. In principle, retatrutide combines reduced caloric intake (via GLP-1 and GIP) with increased energy expenditure (via glucagon), rather than relying on intake reduction alone. Whether that theoretical additive effect translates cleanly into proportionally greater outcomes in humans is exactly what the trial program is designed to test.

The same glucagon receptor activity raises resting heart rate — a pharmacological consequence that has drawn specific research attention and is discussed further below.

Phase 2 Results: Weight Loss Signal

The Phase 2 trial, published in 2023, enrolled participants with obesity and tested multiple dose tiers over 48 weeks. At the highest dose, participants lost a mean of approximately 24% of body weight — a larger average reduction than semaglutide or tirzepatide had shown at comparable trial durations. That cross-trial comparison carries the standard caveats: these are different populations, different trial designs, and not a head-to-head. The number should be read as a signal, not a ranking.

This was a dose-finding and signal-generating study with a few hundred participants. Phase 2 trials are not designed to confirm efficacy at scale or to establish long-term safety — that is what Phase 3 is for. A meaningful proportion of drugs that produce strong Phase 2 results do not replicate that effect size in larger, longer trials, or surface new safety signals when the population broadens.

Phase 3 Results: TRIUMPH-3 and Cardiovascular Outcomes

The first substantial Phase 3 data to become public comes from TRIUMPH-3, an Eli Lilly–sponsored trial testing retatrutide in people with obesity who also had established cardiovascular disease — the population at highest risk for adverse cardiac events, and the most direct stress test of the drug's cardiac safety given its heart-rate–elevating mechanism.

Participants received placebo or retatrutide at 9 mg or 12 mg weekly. The primary outcome was major adverse cardiovascular events (MACE): a composite of cardiovascular death, heart attack, stroke, heart failure hospitalisation, and coronary revascularisation.

The retatrutide groups recorded 44 MACE events versus 52 in the placebo group, yielding a hazard ratio of 0.82 — an apparent 18% reduction. This did not reach statistical significance; the confidence interval crossed 1.0, meaning the result is consistent with chance. TRIUMPH-3 should not be read as proof of cardiovascular protection, though the direction of the trend is notable.

Beyond MACE, the highest dose produced the following biomarker changes in TRIUMPH-3:

  • Triglycerides fell 37%
  • Non-HDL cholesterol dropped 16.5%
  • Systolic blood pressure decreased 9.3 mmHg
  • Waist circumference reduced 19 cm
  • High-sensitivity C-reactive protein (hsCRP) fell 51%

The lipid and blood pressure effects are directionally consistent with what the GLP-1 class has shown broadly. The hsCRP reduction of over 50% is larger than typically seen and is worth noting if systemic inflammation is part of your monitoring framework, though a single industry-sponsored trial is not sufficient to draw strong conclusions about mechanism or durability.

Side Effect Profile

Retatrutide's Phase 2 data showed a gastrointestinal side effect profile similar in kind to semaglutide and tirzepatide: nausea, diarrhoea, and vomiting, concentrated during dose titration. This is expected from a molecule built around GLP-1 agonism as one of its three components.

The resting heart rate elevation associated with glucagon receptor activity is a real finding, not a theoretical concern. TRIUMPH-3 was in part designed to determine whether that elevation caused net harm in a high-risk cardiac population. The MACE trend — while not statistically definitive — favoured retatrutide rather than showing harm, which is a degree of reassurance. It does not eliminate the heart rate signal, and monitoring via wearable data during any future clinical use would be reasonable.

What the Evidence Does and Does Not Show

To be clear about where the evidence stands:

  • Phase 2 weight loss data (~24% body weight) is the strongest average reported in this drug class to date, but from a small, short trial not designed to confirm that magnitude at scale.
  • TRIUMPH-3 is the first Phase 3 dataset available publicly. It shows a directionally favourable cardiovascular trend that did not reach statistical significance, alongside substantial improvements in cardiovascular risk biomarkers.
  • The trial is industry-funded by Eli Lilly; independent replication has not yet occurred.
  • Long-term outcome data beyond the TRIUMPH-3 trial window are not yet available.
  • Retatrutide is not approved by the FDA and is not commercially available as a prescription drug as of the time of publication. Regulatory status remains unresolved.

The Phase 3 trial program for obesity is not complete. TRIUMPH-3 represents one trial within a broader program, and approval will depend on the full dataset.

What MyKine Users Might Track or Watch For

If you are following this drug's development or using it in a research or grey-market context, the biomarkers most relevant to its mechanism are:

  • Body weight and body composition — the primary efficacy signal in trials
  • Resting heart rate — wearable data is adequate for trend monitoring; this is the mechanism-driven safety parameter most worth watching
  • Lipid panel (especially triglycerides and non-HDL cholesterol) — TRIUMPH-3 showed large reductions; useful to baseline before and track during
  • hsCRP — if inflammation is part of your health model; the 51% reduction in TRIUMPH-3 is notable but needs further corroboration
  • Systolic blood pressure — consistent improvement seen across GLP-1-class agents and in TRIUMPH-3 specifically
  • GI symptom log — nausea and GI disturbance are the most common early tolerability issue; tracking against dose titration schedule helps identify whether symptoms are transient

Practical Takeaway

  • Retatrutide's triple-receptor mechanism is a genuine biological step beyond tirzepatide — the glucagon component adds an energy-expenditure pathway that dual agonists lack.
  • Phase 2 data showed approximately 24% mean weight loss over 48 weeks at the highest dose, the largest average reported in this class, but from a small dose-finding trial not built to confirm that number.
  • TRIUMPH-3 (Phase 3) showed an 18% apparent reduction in MACE in a high-risk cardiovascular population — directionally favourable but not statistically significant; do not interpret this as proven cardiac protection.
  • Biomarker improvements in TRIUMPH-3 (triglycerides −37%, hsCRP −51%, blood pressure −9.3 mmHg) are substantial and worth tracking against your own baseline if you have access to this drug.
  • The resting heart rate elevation from glucagon agonism is real; TRIUMPH-3 suggests it did not cause net cardiovascular harm in this population, but monitoring remains appropriate.
  • Retatrutide is not approved and not commercially available; all data to date is from industry-sponsored trials, and the full Phase 3 program is not yet complete.

Sources